OUR QUEST IS NOT TO BE BULLISH OR BEARISH, BUT TO CORRECTLY ASSESS FUTURE TRENDS

Morgans rates NUZ as Speculative Buy

Morgans notes Neurizon Therapeutics has finished its enrollment in Regimen for the trial for NUZ-100. All 260 participants were enrolled with the efficacy and safety results pulled forward to late 2Q2027 from 3Q2027.

The analyst highlights completion was under five months from the initial dosing and is the speediest regimen activation and completion in Healey's history.

Notably, the broker stresses the clinical risk remains, despite the pull forward on the timeline.

Speculative Buy rating and 20c target are unchanged.

Citi rates QBE as Neutral

Citi notes insurance stocks have performed relatively well since March and the sector's average PER is around 16x compared to circa 11x in 2022.

The valuation re-rating removes much of the appeal for the sector, the analyst believes, with only nib Holdings ((NHF)) the remaining stock ascribed a Buy rating.

QBE Insurance is Neutral rated with an unchanged $27.20 target price. The general insurer is expected to have a "solid" 1H2026 result to achieve 2026 earnings guidance.

Bell Potter rates WTC as Buy

Bell Potter believes WiseTech Global could be the next large-cap technology stock to rally as recent headwinds begin to ease.

Commentary notes headwinds include governance concerns, uncertainty around customer DSV and expectations for FY26 results and FY27 guidance.

The broker expects the company to meet FY26 guidance and believes reduced market expectations increase the likelihood FY27 guidance meets consensus.

Positive commentary around customer migration to the new pricing model could provide a further catalyst, Bell Potter suggests.

Buy retained. Target unchanged at $71.75.